The contract manufacturing market for oligonucleotides is highly fragmented, featuring the presence of established companies, as well as emerging start-ups. Close to 45% of the companies engaged in this domain are headquartered in North America; of these, majority are mid-sized players (14%), followed by large and small firms (13% each). Majority (72) of the companies synthesize RNA oligonucleotides, such as small interfering RNA (siRNA) (49), micro-RNA (miRNA) (25) and Decoy RNA (8). This can be attributed to the various advantages offered by RNA oligonucleotides, including high specificity, gene expression regulation and relative safety. In addition, close to 45% of the synthesis providers offer services across all scales of operations. Further, close to 90% of the players offer purification services.
Read More;
https://www.rootsanalysis.com/reports/oligonucleotide-synthesis/304.htmlDuring our research, we came across 64 partnerships that have been inked by various stakeholders engaged in the oligonucleotide synthesis market, during the period 2014-2023 (till September). It is worth noting that in 2023, acquisitions (34%) emerged as the most popular type of partnership model adopted by players engaged in the oligonucleotide synthesis domain. This can be attributed to the incessant efforts of players to further advance the development of their oligonucleotide products. This is followed by manufacturing agreements (16%) and service alliances (14%).
In order to accommodate their growing businesses, contract manufacturers are heavily investing in either expanding their existing facilities / capabilities or construct / acquire new facilities in other geographies. During our research, we identified close to 60 expansion initiatives that have been undertaken in the oligonucleotide synthesis industry, during the period 2015-2023. As can be observed in the figure, majority of the expansion initiatives undertaken by the oligonucleotide synthesis providers were reported during the period 2021. This can be attributed to the indubitably rising demand for oligonucleotides in the COVID-19 pandemic.
Owing to several factors, including globalization and introduction of political and regulatory reforms, advanced contract manufacturing services for oligonucleotides are no longer confined to the developed geographies alone. Currently, several players in emerging geographies, such as those based in China, India, Asia-Pacific and Latin America, offer high quality contract manufacturing services for oligonucleotides, along with providing lucrative cost benefits.
Browse More Related:
Medical Polymers Market
https://www.rootsanalysis.com/reports/medical-polymers-market.htmlModular Construction Market
https://www.rootsanalysis.com/reports/modular-manufacturing-market/178.htmlNutrigenomics Market
https://www.rootsanalysis.com/reports/nutrigenomics-market.html
Locked
